Fredun Pharmaceuticals share price today

Fredun Pharmaceuticals Ltd's share price was ₹1,508.70 at the close on 4 November 2026. It has been rising for 70 weeks. That is 49.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹479 and ₹1,553, and at that close it sat 96% of the way up from that low.

A share price tends to move through four phases: moving sideways (stage 1), rising (stage 2), stalling near a high (stage 3) and falling (stage 4). Today Fredun Pharmaceuticals Ltd is in stage 2. The phase helps read everything below.

Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 20 weeks in a row.

Over the last 11 years the share price moved +36,080% while the NIFTY 500 moved +243%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week.

This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row.

Three changes stood out: revenue up on a year earlier for 11 quarters in a row (every quarter we can compare), profit up on a year earlier for 7 quarters in a row and highest quarterly profit in 15 quarters.

1. Revenue up on a year earlier for 11 quarters in a row (every quarter we can compare)

   In the June 2026 quarter revenue was ₹228 crore, +90% on a year earlier.

   Why: Revenue rose because the company had stocked ingredients earlier, protected customer prices and got extra orders.

   From the earnings call on 13 Aug 2026.

2. Profit up on a year earlier for 7 quarters in a row

   In the June 2026 quarter profit was ₹13 crore, +85.7% on a year earlier.

   Why: Profit rose because more of the sales came from higher margin newer products and better registrations in older markets.

   Next results: check whether the share of sales left as profit rises from selling more higher margin products and repeat orders, not from giving up profit.

   From the earnings call on 13 Aug 2026.

3. Highest quarterly profit in 15 quarters

   Profit of ₹13 crore in the June 2026 quarter is the highest of the last 15 quarters.

   Why: The record profit came from the same shift to higher margin newer products, better registrations in older markets and deeper customer reach.

   Next results: check whether the share of sales left as profit keeps improving as newer products sell more.

   From the earnings call on 13 Aug 2026.

For April to June 2026 (the quarter ended 30 June 2026), Fredun Pharmaceuticals reported revenue of ₹228 crore, up 90.0% from ₹120 crore a year earlier, and a profit of ₹13.0 crore, up 85.7% from ₹7.00 crore.

Fredun Pharmaceuticals results: April to June 2026 against a year earlier

The next results, for July to September 2026, are due by 14 November 2026: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter).

Fredun Pharmaceuticals' management discussed these results on a call held on 13 August 2026; what it said is further down this page.

From the company's reported quarterly results (quarter ended 30 June 2026). Revenue and profit in ₹ crore.

Fredun Pharmaceuticals closed at ₹1,508.70 on 4 November 2026, up 191.8% from ₹517.10 a year earlier (7 November 2025) and up 793.8% over five years. Its highest weekly close since March 2016 was ₹1,553.15 on 9 October 2026.

Fredun Pharmaceuticals share price: then and now

Weekly closing prices, adjusted for splits and bonuses so every price is on today’s share count. Each change is the move from that price to the 4 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes.

492 weekly closes from 28 March 2016 to 4 November 2026.

4 Nov 2026: Fredun Pharmaceuticals closed at ₹1,508.70, up 10.4% on the week and up 11.5% on the month. 13 Aug 2026: Fredun Pharmaceuticals held its results call for April to June 2026. Management guided: New-age brands 35-45% annually and vintage business 15-20%; blended company growth 35-40% over 3 years; Fredun GX 25-35% over 5 years, or 30-35% over 4 years.

Earlier

• Results for April to June 2026: Revenue up 90.0% and profit up 85.7% on a year earlier.

The NSE corporate-actions record has no dividend for Fredun Pharmaceuticals since 1 April 2021, so this page cannot show amounts per share.

Yes. Fredun Pharmaceuticals Ltd paid out 1% of its profit as dividends in FY26, and it paid a dividend in 11 of its last 13 reported years.

From the NSE corporate-actions record, read 5 November 2026.

On the call for April to June 2026, held on 13 August 2026, Fredun Pharmaceuticals' management guided: New-age brands 35-45% annually and vintage business 15-20%; blended company growth 35-40% over 3 years; Fredun GX 25-35% over 5 years, or 30-35% over 4 years.

“A blended growth of somewhere around 35-40% for the next 3 years is on the charts.”Fredun Medhora, MD, on the call for April to June 2026

What management guided

• FY27 revenue goal around ₹800 crore; coming quarters and next year expected to sustain a similar growth pace.
• Pet-care growth 40-50% annually over 3-4 years; cat-food launch expected Q3/January to March 2027 and its business planned at ₹100 crore within 3-3.5 years of launch.
• Wagr brand onboarding within 20-25 days, beta work within 60-65 days and major campaigns within 90 days.
• Capital spending ₹30-40 crore in FY27 and similar next year, broader two-year framing ₹35-45 crore annually; supports a top-tier single-location unit by end-December 2028 or early 2029.

Management’s own plans and goals, from our notes of the call. A plan is not a result.

Source: the call transcript.

From the call for April to June 2026, 13 August 2026.

When Fredun Pharmaceuticals reports July to September 2026, these are the 4 checks that show whether the story is still on course. First: Revenue trajectory versus the stated annual goal - check whether growth stays near Q1 pace after prior-quarter stocking benefits normalize.

Fredun Pharmaceuticals is on 2 of our India lists: Momentum stocks and Pharma stocks.

Fredun Pharmaceuticals Ltd earned ₹13.0 Cr of net profit in the Jun 2026 quarter, +85.7% on the same quarter a year earlier. That is the 7th quarter in a row of profit growth. Full-year FY26 profit was ₹33.0 Cr. Over 10 years profit has grown 41.9% a year on average. That is 5.7% of the quarter's revenue.

Net profit is what is left after every cost, interest and tax. Earnings per share, dividends and book value all grow from it.

The same quarter a year earlier earned ₹7.0 Cr.

For the full year, FY26 profit was ₹33.0 Cr (+57.1% on the year before).

Why profit moved: revenue changed +90.0% on a year earlier and the margin moved +0.0 percentage points. Sales did the work, and the margin was about flat.

On average over the last four quarters, profit changed +98.2% and revenue +52.3%. Profit is growing faster than sales: fixed costs are spread over more sales, so each extra rupee of revenue adds more to profit.

Fredun Pharmaceuticals Ltd reported ₹228 Cr of revenue in the Jun 2026 quarter, +90.0% on the same quarter a year earlier. That is the 12th quarter in a row with growth on the year before. Over 10 years it has grown 31.2% a year on average. The last full year, FY26, came in at ₹635 Cr.

Revenue is everything the company billed its customers in the period.

The last four reported quarters add to ₹747 Cr.

FY26 revenue was ₹635 Cr, +39.9% on the year before.

Recent pace: the last four quarters grew +52.3% on average, against 31.2% a year over the longer run, so this year is growing faster than its own long-run rate.

Is growth speeding up? Revenue over the last 12 months grew +50.3%, against +42.9% a year over the last 8 quarters (accelerating); profit over the last 12 months grew +91.3%, against +60.9% a year (accelerating).

Fredun Pharmaceuticals Ltd's operating margin was 14.0% in the Jun 2026 quarter, about the same as the same quarter a year ago. Its latest full-year margin is the highest it has ever reported. Across 13 years it has been between 6.0% and 14.0%. The latest quarter is within that range.

Operating margin is what is left from every ₹100 of sales after the costs of running the business, before interest and tax. It shows pricing power and cost control.

In the latest quarter it moved +0.0 percentage points on the same quarter a year ago.

Why the margin moved: operating margin changed +0.2 percentage points on the year while gross margin changed −5.5 points. So the gain came mostly from the gross margin, which means input costs and prices charged.

When margins are at a record, every ratio built on profit looks better than usual, so watch whether they hold.

Over the last 3 years Fredun Pharmaceuticals Ltd's operations used more cash than they brought in, so cash conversion was −7%, a gap worth watching. In FY26 it brought in ₹16.0 Cr of operating cash against ₹33.0 Cr of profit. After ₹73.0 Cr of spending on assets, free cash was −₹57.0 Cr: it spent more than its operations brought in.

The profit and loss account shows what was earned. The cash-flow statement shows the cash that actually came in. Comparing operating cash flow with profit is one of the best checks that a profit is real.

Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year.

Why −7% of profit came in as cash: the cash cycle got 62 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page.

What to look at next: less of the profit turns into cash than it should, and the cash cycle is 62 days longer. The next section looks at where the cash is stuck.

Fredun Pharmaceuticals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 201 days in FY26, up from 139 days in FY21. It spent ₹95.0 Cr on assets over the last 3 years. Customers take 53 days to pay, and stock sits for 219 days on average.

Working capital is the cash tied up between paying suppliers and getting paid. Debtor days: how long customers take to pay. Inventory days: how long stock sits. The cash cycle: the whole loop, in days of sales.

At FY26 sales of ₹635 Cr, each day of that cycle ties up about ₹1.7 Cr, so roughly ₹350 Cr is tied up in the business at any time.

FY26: customers took 53 days to pay and stock sat for 219 days, about 7.2 months of sales sitting as stock, for a full cycle of 201 days, longer than FY21's 139.

The full loop: cash goes out to suppliers and production on day 0. Stock sits for 219 days. Customers pay about 53 days after that. Suppliers are paid at 71 days. Together that makes the 201-day cycle.

Spending on assets: ₹95.0 Cr over the last 3 years, against ₹16.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹0.0 Cr (FY26): assets paid for that are not earning yet.

In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit.

Fredun Pharmaceuticals Ltd's P/E is 58.2×, near the high end of its own history: higher than 81% of past readings. Its usual P/E (the middle reading) is 33.3×, over 11 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth.

P/E is the share price divided by a year's profit per share: how many rupees the market pays for each rupee of yearly profit.

The P/E here, and its history, use a profit figure that can leave out one-off items, so it can differ from a P/E worked out on the quarterly results. Those results' earnings per share for the four quarters to Jun 2026 add up to ₹28.09.

Why the multiple is where it is: over the past year earnings per share moved +38.2% while the price moved +191.8%. The price did better than earnings, which pushed the multiple up within its own range.

Where the price move came from: over 5 years the price moved +55.0% a year; about +48.0% a year came from earnings growth and about +7.0 percentage points from the multiple (the market paying more); over 10 years the price moved +60.9% a year; about +27.3% a year came from earnings growth and about +33.6 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple.

In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple.

Fredun Pharmaceuticals Ltd's business is getting better. EPS growth hit its low 8 quarters ago at −39.8% and has recovered to +70.1%, with ROCE rising at 40.5%. This is based on 12 quarters of 4 measures.

Every business is somewhere on a path of getting better or worse, and this section names where. The last 12 quarters of growth in revenue, profit and earnings per share, plus the return the business earns on its capital, are read as lines. Getting worse: the lines are falling. Turning around: a low point has just formed and the last few quarters are rising from it. Getting better: the rise from the low has lasted. Growing steadily: steady growth with healthy returns. Slowing from a peak: still high, but slowing. When the lines disagree the result is mixed; too little history means no reading. CAGR (compound annual growth rate) is the steady yearly rate that would turn the starting value into the latest one. It is the fairest way to compare growth over different periods. If the 1-year figure is much bigger than the 10-year one, recent growth is running faster than the long-run trend. A dash means there is no figure for that period, or the starting year was a loss, where a growth rate means nothing.